サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463060

遅発性ジスキネジア治療薬市場、シェア、規模、動向、産業分析レポート：薬剤別、 製品タイプ別、 販売チャネル別、 地域別、 セグメント別予測、2024年～2032年

Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

出版日
ページ情報
英文 117 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
遅発性ジスキネジア治療薬市場、シェア、規模、動向、産業分析レポート：薬剤別、 製品タイプ別、 販売チャネル別、 地域別、 セグメント別予測、2024年～2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、遅発性ジスキネジア治療薬の世界市場規模は2032年までに55億7,000万米ドルに達する見込みです。本レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

様々な神経疾患や精神病性疾患の有病率の急激な増加、疾患特異的な新規治療へのニーズの高まりが、市場成長を促進する主要因となっています。さらに、新規介入を進めるための研究者や医療機関への財政支援の増加や、遅発性ジスキネジア治療薬を含むヘルスケア分野でのイノベーションが、市場の成長をさらに促進すると予測されています。

例えば、2023年11月、Neurocrine Biosciences社は、医療従事者が遅発性ジスキネジアについて学び、識別するのを助けるために特別に設計された対話型デジタルツールであるDISCOVER TDを発表しました。このツールは臨床専門家と共同で開発されました。

不規則なドーパミンを引き起こす抗精神病薬による長期治療を必要とする精神疾患の症例が世界中で増加しており、効果的な治療薬への需要が高まっています。また、認知機能の変化のモニタリングや検出、特定のパターンの特定、情報処理速度の向上のための神経心理学的検査の採用が増加していることも、市場の成長を後押ししています。例えば、米国疾病予防管理センターの報告書によると、米国の成人の5人に1人近くが何らかの精神疾患を抱えて生活しており、若者の5人に1人近くが生涯のうちに深刻な精神疾患を患っています。

さらに最近、米国神経学会のガイドラインが更新され、バルベナジンおよびドイテトラベナジンを含むFDA承認の2つのVMAT2阻害薬が組み込まれました。これらの薬剤はレベルAのエビデンスに裏付けられた最初の薬剤であり、主に米国で遅発性ジスキネジア治療薬として承認されました。

遅発性ジスキネジア治療薬市場レポートハイライト

遅発性ジスキネジアとその治療薬に関する啓蒙活動の高まりにより、バルベナジン製剤が注目すべきシェアを占める

医療専門家による採用の増加と高い投薬効果により、固形製剤セグメントが大半のシェアを占める

オンライン薬局部門は、オンライン購入者の増加や遠隔地向けのオンライン薬局の出現により、最も高いペースで成長すると思われます。

北米が世界市場を席巻、これは同地域の疾患に対する認知度の高さと治療選択肢の幅広さ、そして償還シナリオの良好さによる。

主な市場プレイヤーは、Reddy Laboratories、SOM Biotech、Luye Pharma Group、Prestwick Pharmaceuticals、Sun Pharmaceuticals Industries、Allerganなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 遅発性ジスキネジア治療薬の世界市場の洞察

  • 遅発性ジスキネジア治療薬市場- 流通チャネルスナップショット
  • 遅発性ジスキネジア治療薬市場力学
    • 促進要因と機会
      • 研究開発の取り組み
      • 遅発性ジスキネジアの罹患率の増加と、製品承認の取得に対する企業の重点
    • 抑制要因と課題
      • 病態生理学の理解の限界
  • PESTEL分析
  • 遅発性ジスキネジア治療薬市場の流通チャネル動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 薬剤別の世界市場

  • 主な調査結果
  • イントロダクション
  • デュテトラベナジン
  • バルベナジン
  • その他

第6章 製品タイプ別の世界市場

  • 主な調査結果
  • イントロダクション
  • 固形剤形
  • 錠剤
  • カプセル
  • 液体剤形
  • インジェクション

第7章 流通チャネル別の世界市場

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • ドラッグストアと薬局
  • オンライン薬局
  • その他

第8章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • 遅発性ジスキネジア治療薬市場評価、地域、2019-2032年
  • 遅発性ジスキネジア治療薬市場-北米
    • 北米：遅発性ジスキネジア治療薬市場、薬剤別、2019年～2032年
    • 北米：遅発性ジスキネジア治療薬市場、流通チャネル別、2019年～2032年
    • 北米：遅発性ジスキネジア治療薬市場、製品タイプ別、2019年～2032年
    • 遅発性ジスキネジア治療薬市場-米国
    • 遅発性ジスキネジア治療薬市場- カナダ
  • 遅発性ジスキネジア治療薬市場- 欧州
    • 欧州：遅発性ジスキネジア治療薬市場、薬剤別、2019年～2032年
    • 欧州：遅発性ジスキネジア治療薬市場、流通チャネル別、2019年～2032年
    • 欧州：遅発性ジスキネジア治療薬市場、製品タイプ別、2019年～2032年
    • 遅発性ジスキネジア治療薬市場- 英国
    • 遅発性ジスキネジア治療薬市場- フランス
    • 遅発性ジスキネジア治療薬市場- ドイツ
    • 遅発性ジスキネジア治療薬市場- イタリア
    • 遅発性ジスキネジア治療薬市場- スペイン
    • 遅発性ジスキネジア治療薬市場- オランダ
    • 遅発性ジスキネジア治療薬市場- ロシア
  • 遅発性ジスキネジア治療薬市場- アジア太平洋地域
    • アジア太平洋地域：遅発性ジスキネジア治療薬市場、薬剤別、2019年～2032年
    • アジア太平洋地域：遅発性ジスキネジア治療薬市場、流通チャネル別、2019-2032年
    • アジア太平洋地域：遅発性ジスキネジア治療薬市場、製品タイプ別、2019年～2032年
    • 遅発性ジスキネジア治療薬市場- 中国
    • 遅発性ジスキネジア治療薬市場- インド
    • 遅発性ジスキネジア治療薬市場- マレーシア
    • 遅発性ジスキネジア治療薬市場- 日本
    • 遅発性ジスキネジア治療薬市場- インドネシア
    • 遅発性ジスキネジア治療薬市場- 韓国
  • 遅発性ジスキネジア治療薬市場-中東およびアフリカ
    • 中東およびアフリカ：遅発性ジスキネジア治療薬市場、薬剤別、2019-2032年
    • 中東およびアフリカ：遅発性ジスキネジア治療薬市場、流通チャネル別、2019-2032年
    • 中東およびアフリカ：遅発性ジスキネジア治療薬市場、製品タイプ別、2019-2032年
    • 遅発性ジスキネジア治療薬市場- サウジアラビア
    • 遅発性ジスキネジア治療薬市場-UAE
    • 遅発性ジスキネジア治療薬市場- イスラエル
    • 遅発性ジスキネジア治療薬市場- 南アフリカ
  • 遅発性ジスキネジア治療薬市場-ラテンアメリカ
    • ラテンアメリカ：遅発性ジスキネジア治療薬市場、薬剤別、2019年～2032年
    • ラテンアメリカ：遅発性ジスキネジア治療薬市場、流通チャネル別、2019年～2032年
    • ラテンアメリカ：遅発性ジスキネジア治療薬市場、製品タイプ別、2019年～2032年
    • 遅発性ジスキネジア治療薬市場- メキシコ
    • 遅発性ジスキネジア治療薬市場- ブラジル
    • 遅発性ジスキネジア治療薬市場- アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第10章 企業プロファイル

  • Allergan
  • Contera Pharma
  • Johnson & Johnson Services Inc.
  • Lannett Co. Inc
  • Luye Pharma Group
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences Inc.
  • Prestwick Pharmaceuticals Inc.
  • Reddy Laboratories Ltd.
  • SOM Biotech
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals
図表

List of Tables

  • Table 1 Global Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 2 Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 3 Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 6 North America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 7 North America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 9 U.S.: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 12 Canada: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 15 Europe: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 18 UK: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 19 UK: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 21 France: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 22 France: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 24 Germany: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 27 Italy: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 30 Spain: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 36 Russia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 42 China: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 43 China: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 45 India: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 46 India: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 51 Japan: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 57 South Korea: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 66 UAE: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 69 Israel: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 72 South Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 75 Latin America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 78 Mexico: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 81 Brazil: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • Table 84 Argentina: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Tardive Dyskinesia Therapeutics Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Product Type
  • Figure 7. Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug
  • Figure 9. Global Tardive Dyskinesia Therapeutics Market, by Drug, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Tardive Dyskinesia Therapeutics Market
目次
Product Code: PM4423

The global tardive dyskinesia therapeutics market size is expected to reach USD 5.57 billion by 2032, according to a new study by Polaris Market Research. The report "Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The drastic increase in the prevalence of various neurological and psychotic disorders and growing need for disease-specific novel treatment, are the leading factors propelling market's growth. Additionally, increase in financial support to the researchers and health institutes for advancing the novel intervention and bring innovations in the healthcare sector including therapeutics for tardive dyskinesia, are further anticipated to drive market's growth.

For instance, in November 2023, Neurocrine Biosciences, introduced DISCOVER TD, which is an interactive digital tool specially designed to help healthcare providers learn and identify about the tardive dyskinesia. Tool is built in collaboration with the clinical experts.

The rising cases of mental illnesses across the globe which requires prolonged treatment with antipsychotic drugs that causes irregular dopamine, fostering the demand for effective therapeutics. Also, the growing adoption of neuropsychological testing for monitoring or detecting changes in cognitive function, identifying specific patterns, and speed of information processing, are also propelling the market's growth. For instance, as per a report by the Centers for Disease Control and Prevention, nearly 1 in 5 US adults live with some form of mental illness, & nearly1 in 5 youth have seriously debilitating mental illness during their life.

Furthermore, the guideline of the American Academy of Neurology was updated recently for incorporating 2 FDA-approved VMAT2 inhibitors including valbenazine & deutetrabenazine, which has been marked as a huge milestone because they had undergone multi-center, randomized, & double-blind clinical trials. They were the first one which is going to be supported by the level A evidence and were mainly approved for the treatment of tardive dyskinesia in the United States.

Tardive Dyskinesia Therapeutics Market Report Highlights

Valbenazine segment accounted for the noteworthy share, on account of rising number of awareness campaigns about such diseases and their therapeutics

Solid dosage form segment held the majority share, driven by its rising adoption by healthcare professionals and higher effectiveness of medication

Online pharmacies segment will grow at highest pace, due to rising number of online buyers and emergence of several online pharmacies for the remotest places

North America dominated the global market, owing to region's greater awareness about disease and wider availability of treatment options, coupled with positive reimbursement scenario

The key market players include Reddy Laboratories, SOM Biotech, Luye Pharma Group, Prestwick Pharmaceuticals, Sun Pharmaceuticals Industries, and Allergan

Polaris Market Research has segmented the tardive dyskinesia therapeutics market report based on drug, product type, distribution channel, and region:

Tardive Dyskinesia Therapeutics, Drug Outlook (Revenue - USD Billion, 2019 - 2032)

  • Deutetrabenazine
  • Valbenazine
  • Others

Tardive Dyskinesia Therapeutics, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Solid Dosage Forms
  • Tablets
  • Capsules
  • Liquid Dosage Form
  • Injection

Tardive Dyskinesia Therapeutics, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Others

Tardive Dyskinesia Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Tardive Dyskinesia Therapeutics Market Insights

  • 4.1. Tardive Dyskinesia Therapeutics Market - Distribution Channel Snapshot
  • 4.2. Tardive Dyskinesia Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Research and Development Initiatives.
      • 4.2.1.2. Increasing prevalence of tardive dyskinesia and focus of companies on gaining product approvals are propelling market growth.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Understanding of Pathophysiology
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Tardive Dyskinesia Therapeutics Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Tardive Dyskinesia Therapeutics Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
  • 5.3. Deutetrabenazine
    • 5.3.1. Global Tardive Dyskinesia Therapeutics Market, by Deutetrabenazine, by Region, 2019-2032 (USD Billion)
  • 5.4. Valbenazine
    • 5.4.1. Global Tardive Dyskinesia Therapeutics Market, by Valbenazine, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Tardive Dyskinesia Therapeutics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Tardive Dyskinesia Therapeutics Market, by Product Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 6.3. Solid Dosage Form
    • 6.3.1. Global Tardive Dyskinesia Therapeutics Market, by Solid Dosage Form, by Region, 2019-2032 (USD Billion)
  • 6.4. Tablets
    • 6.4.1. Global Tardive Dyskinesia Therapeutics Market, by Tablets, by Region, 2019-2032 (USD Billion)
  • 6.5. Capsules
    • 6.5.1. Global Tardive Dyskinesia Therapeutics Market, by Capsules, by Region, 2019-2032 (USD Billion)
  • 6.6. Liquid Dosage Form
    • 6.6.1. Global Tardive Dyskinesia Therapeutics Market, by Liquid Dosage Form, by Region, 2019-2032 (USD Billion)
  • 6.7. Injection
    • 6.7.1. Global Tardive Dyskinesia Therapeutics Market, by Injection, by Region, 2019-2032 (USD Billion)

7. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Hospitals Pharmacies
    • 7.3.1. Global Tardive Dyskinesia Therapeutics Market, by Hospitals Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Drug Stores & Retail Pharmacies
    • 7.4.1. Global Tardive Dyskinesia Therapeutics Market, by Drug Stores & Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Online Pharmacies
    • 7.5.1. Global Tardive Dyskinesia Therapeutics Market, by Online Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Tardive Dyskinesia Therapeutics Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Tardive Dyskinesia Therapeutics Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Tardive Dyskinesia Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Tardive Dyskinesia Therapeutics Market - North America
    • 8.3.1. North America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.3.2. North America: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.3.4. Tardive Dyskinesia Therapeutics Market - U.S.
      • 8.3.4.1. U.S.: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.3.5. Tardive Dyskinesia Therapeutics Market - Canada
      • 8.3.5.1. Canada: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.4. Tardive Dyskinesia Therapeutics Market - Europe
    • 8.4.1. Europe: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.4. Tardive Dyskinesia Therapeutics Market - UK
      • 8.4.4.1. UK: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.5. Tardive Dyskinesia Therapeutics Market - France
      • 8.4.5.1. France: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.6. Tardive Dyskinesia Therapeutics Market - Germany
      • 8.4.6.1. Germany: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.7. Tardive Dyskinesia Therapeutics Market - Italy
      • 8.4.7.1. Italy: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.8. Tardive Dyskinesia Therapeutics Market - Spain
      • 8.4.8.1. Spain: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.9. Tardive Dyskinesia Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.4.10. Tardive Dyskinesia Therapeutics Market - Russia
      • 8.4.10.1. Russia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.5. Tardive Dyskinesia Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.4. Tardive Dyskinesia Therapeutics Market - China
      • 8.5.4.1. China: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.5. Tardive Dyskinesia Therapeutics Market - India
      • 8.5.5.1. India: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.6. Tardive Dyskinesia Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.7. Tardive Dyskinesia Therapeutics Market - Japan
      • 8.5.7.1. Japan: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.8. Tardive Dyskinesia Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.5.9. Tardive Dyskinesia Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.6. Tardive Dyskinesia Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.4. Tardive Dyskinesia Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.5. Tardive Dyskinesia Therapeutics Market - UAE
      • 8.6.5.1. UAE: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.6. Tardive Dyskinesia Therapeutics Market - Israel
      • 8.6.6.1. Israel: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.6.7. Tardive Dyskinesia Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
  • 8.7. Tardive Dyskinesia Therapeutics Market - Latin America
    • 8.7.1. Latin America: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.7.4. Tardive Dyskinesia Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.7.5. Tardive Dyskinesia Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)
    • 8.7.6. Tardive Dyskinesia Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Tardive Dyskinesia Therapeutics Market, by Drug, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Tardive Dyskinesia Therapeutics Market, by Product Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Allergan
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Contera Pharma
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Johnson & Johnson Services Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Lannett Co. Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Luye Pharma Group
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Mitsubishi Tanabe Pharma Corporation
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Neurocrine Biosciences Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Prestwick Pharmaceuticals Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Reddy Laboratories Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. SOM Biotech
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. SteriMax Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Sun Pharmaceutical Industries Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Teva Pharmaceutical Industries Ltd.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Valeant Pharmaceuticals
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development